@article {YooP2810, author = {Jung-Wan Yoo and Jiwon Lyu and Sang Do Lee and Woo Sung Kim and Dong Soon Kim and Tae Sun Shim}, title = {Clinical experience of clofazimine in the treatment of MDR-TB}, volume = {42}, number = {Suppl 57}, elocation-id = {P2810}, year = {2013}, publisher = {European Respiratory Society}, abstract = {Objective:In vitro studies have shown good activity of clofazimine against Mycobacterium tuberculosis, including multidrug-resistant strains. However,clinical experience with clofazimine in tuberculosis is scarce. We report, here,our clinical experience with 32 consecutive patients with multidrug-resistant tuberculosis (MDR-TB) treated with clofazimine-containing regimens. Methods:Record review was performed for 32 patients treated with clofazimine as part of a MDR-TB regimen. Patients were enrolled until December 2011. Data were collected on clinical and microbiological characteristics, clofazimine tolerability, and treatment outcomes. The usual dosage of clofazimine was 150mg daily. Results:Patients had isolates resistant to a median of 9 drugs(range,4-13 drugs). Clofazimine was added to MDR-TB regimens for a median duration of 7 months(range;1-22). Eleven patients discontinued clofazimine because of out of stock. At data censure(15 February 2013), one patient continued to receive clofazimine-containing regimen. Culture conversion rate was 53.1\%(17/32). The treatment success and failure rates were 48.4\%(15/31) and 51.6\%(16/31), respectively. Of 15 treatment success cases, 10(66.7\%) patients were treated with linezolid, and 3(20\%) patients underwent surgical resection. Skin discoloration occurred in all patients and nine patients stopped clofazimine treatment due to adverse effects: skin discolorization(n=3), liver toxicity(n=3), and gastrointestinal disturbance(n=3). Factors for treatment success were men and concurrent use of linezolid in multivariate analysis.Conclusions:The efficacy of clofazimine in the treatment of MDR-TB was considered limited and concurrent use of linezolid may contribute to treatment success.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/42/Suppl_57/P2810}, eprint = {https://erj.ersjournals.com/content/42/Suppl_57/P2810.full.pdf}, journal = {European Respiratory Journal} }